The World of Health & Medicine News

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins

Investors managing $11.5 trillion urge food companies to diversify away from animal proteins

 Investors managing $11.5 trillion in assets are calling on major food companies and retailers to diversify into more plant-based protein sources to enhance supply chain resiliency and mitigate food security risks.

As global interest rates and prolonged higher temperatures help lift feed costs, and with prices for products such as eggs susceptible to unpredictable bird flu outbreaks, food companies are facing increasingly brittle animal supply chains and risk investor divestment should their exposure be deemed too high.

A group of 73 investors engaging in the Farm Animal Investment Risk and Return Initiative investor network are calling on manufacturers and retailers to seize the “growth and health” opportunities alternative protein sources present, according to a FAIRR report set for publication on Tuesday.

Through FAIRR, the investors have engaged with 20 companies, including manufacturers Nestle, Danone and Kraft Heinz and retailers Amazon, Carrefour and Walmart.

“For food and retail, protein diversification is a key element to reduce your CO2 emissions,” Sophie Kamphuis, senior advisor for responsible investment at Dutch asset manager MN, told Reuters.

“We like it if companies set sales targets and launch products, but we also want that to be replacing animal proteins,” Kamphuis added, naming Ahold Delhaize’s (AD.AS), opens new tab target for its European retailers – committing to 50% of proteins sold being plant-based by 2030 – as a good example.

Private investment in non-meat protein sources, such as beans, pulses, plant-based alternatives to animal products and novel methods like cell cultivation, fell to just over $1 billion last year, from a spike of almost $7 billion in 2021, according to The Good Food Institute.

When it comes to protein diversification that focuses on meat substitutes, the recurring problem has been that the products are just not good enough, Jo Raven, director of thematic research and corporate innovation at FAIRR, told Reuters.

“The reality is they did not get the taste and texture right, and consumers are fickle creatures,” Raven said. “So if they purchase it once and just didn’t like it, they’re going to be a harder group to convince otherwise.”

spot_img

Explore more

spot_img

US, European regulators set principles for ‘good AI practice’ in drug...

US, European regulators set principles for 'good AI practice' in drug development The U.S. Food and Drug Administration and the European Medicines Agency jointly issued...

8 Spices With More Anti-Inflammatory Benefits Than Turmeric

8 Spices With More Anti-Inflammatory Benefits Than Turmeric Certain spices can help reduce inflammation, a key factor in chronic conditions like diabetes and heart disease....

Sarepta’s Duchenne gene therapy slows disease progression, three-year data shows

Sarepta's Duchenne gene therapy slows disease progression, three-year data shows Sarepta Therapeutics' gene therapy for a muscle‑wasting disorder slowed disease progression and showed sustained benefit...

Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage...

Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial Eli Lilly (LLY.N), opens new tab said on Thursday a late-stage trial showed its weight-loss...

US withdraws from the World Health Organization

US withdraws from the World Health Organization The United States officially left the World Health Organization on Thursday after a year of warnings that doing...

This Popular Supplement May Help Inhibit Colorectal Cancer Development

This Popular Supplement May Help Inhibit Colorectal Cancer Development New clinical evidence indicates that a widely used supplement may alter gut microbes involved in vitamin...

Short, intensive workouts can help fight bowel cancer

Short, intensive workouts can help fight bowel cancer As many of us embark on an exercise or gym routine for the new year, research reveals...

Neuralink plans ‘high-volume’ brain implant production by 2026, Musk says

Neuralink plans 'high-volume' brain implant production by 2026, Musk says Elon Musk's brain implant company Neuralink will start "high-volume production" of brain-computer interface devices and...